Keyword

harm reduction

Description: A public health approach that seeks to reduce the harmful health and social consequences of risky behaviors without necessarily requiring their cessation.

Primary topic: HIV, Drug Use, Sexual Risk (27%)

Wikidata ID: wiki/Q1458711

OpenAlex ID: keywords/harm-reduction

Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7

2012 · E. Coleman, W. Bockting, et al. · International Journal of Transgenderism · 3,146

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

2014 · Richard P Mattick, Courtney Breen, et al. · Cochrane Database of Systematic Reviews · 2,323

PDF

Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015

2016 · Rose A. Rudd, Puja Seth, et al. · MMWR Morbidity and Mortality Weekly Report · 2,193

PDF

Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies

2017 · Luis Sordo, Gregorio Barrio, et al. · BMJ · 1,813

PDF

Levels of selected carcinogens and toxicants in vapour from electronic cigarettes

2013 · Maciej Lukasz Goniewicz, Jakub Knysak, et al. · Tobacco Control · 1,706

Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence

2009 · Richard P Mattick, Courtney Breen, et al. · Cochrane Database of Systematic Reviews · 1,656

PDF

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial

2013 · Kachit Choopanya, Michael Martin, et al. · The Lancet · 1,464

Housing First, Consumer Choice, and Harm Reduction for Homeless Individuals With a Dual Diagnosis

2004 · Sam Tsemberis, Leyla Gulcur, et al. · American Journal of Public Health · 1,355

The ‘risk environment’: a framework for understanding and reducing drug-related harm

2002 · Tim Rhodes · International Journal of Drug Policy · 1,241

Electronic cigarettes for smoking cessation

2016 · Jamie Hartmann-Boyce, Hayden McRobbie, et al. · Cochrane Database of Systematic Reviews · 1,213

PDF

Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol

2009 · Peter Anderson, Dan Chisholm, et al. · The Lancet · 1,103

Electronic cigarettes for smoking cessation: a randomised controlled trial

2013 · Christopher Bullen, Colin Howe, et al. · The Lancet · 1,100

Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis

2013 · A. Y. Walley, Z. Xuan, et al. · BMJ · 1,000

PDF

Risk environments and drug harms: A social science for harm reduction approach

2009 · Tim Rhodes · International Journal of Drug Policy · 948

Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence

2015 · Gail D’Onofrio, Patrick G. O’Connor, et al. · JAMA · 911

PDF

Cross-cultural adaptation of research instruments: language, setting, time and statistical considerations

2010 · Linn Gjersing, John RM Caplehorn, et al. · BMC Medical Research Methodology · 883

PDF

Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010

2013 · Louisa Degenhardt, Harvey A Whiteford, et al. · The Lancet · 852

Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters

2018 · Marco Del Giudice, Steven W. Gangestad · Brain Behavior and Immunity · 778

Brief intervention for harm reduction with alcohol-positive older adolescents in a hospital emergency department.

1999 · Peter M. Monti, Suzanne M. Colby, et al. · Journal of Consulting and Clinical Psychology · 741

Risk, Uncertainty and Government

2012 · Pat O'Malley · Routledge eBooks · 727

HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage

2010 · Bradley M Mathers, Louisa Degenhardt, et al. · The Lancet · 718

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

2017 · Joshua D Lee, Edward V Nunes, et al. · The Lancet · 703

Tobacco smoking: Health impact, prevalence, correlates and interventions

2017 · Robert West · Psychology and Health · 689

PDF

Acute and Chronic Effects of Cannabinoids on Human Cognition—A Systematic Review

2015 · Samantha J. Broyd, Hendrika H. van Hell, et al. · Biological Psychiatry · 672

Ketamine use: a review

2011 · Celia J. A. Morgan, H. Valerie Curran · Addiction · 666

Works count: 48,810

Citation count: 523,400